2004 was a remarkable year.

- Fortune featured the PCF in its November cover story entitled “Beating Cancer,” and named the PCF as its official philanthropy to celebrate its 75th anniversary.
- For the first time ever, the U.S. Food and Drug Administration approved a drug (Taxotere) that extends life for men with advanced prostate cancer.
- The PCF expanded its donor base by 35%.
- And, significant progress was made in demonstrating the link between nutrition, especially antioxidants, and prostate cancer.

Donations

Please mail your check to:
Prostate Cancer Foundation
1250 Fourth Street
Santa Monica, California 90401

To make an online contribution, please visit our Web site: prostatecancerfoundation.org.

To make a credit card donation, call 800.757.CURE.

Memorial or Tribute Gifts

Honor the memory of a loved one or celebrate the accomplishment of a friend or family member by helping others.

Make a memorial or tribute gift and the PCF will send an acknowledgment card to the family of the honoree.

Other Gift Suggestions

- Assets or property including appreciated stock and real estate.
- Bequest—Include a gift to the PCF in your will.
- Name the PCF as the primary or contingent beneficiary on a life insurance policy.
Fortune magazine noted the PCF and Mike Milken have...

“…managed to raise the profile of prostate cancer significantly, increase funding dramatically to fight the disease, spur innovative research, attract new people to the field, get myriad drugs into clinical trials, and dare we say, speed up science.”

November 29, 2004
Last spring, *Fortune* magazine arrived on our desks with a dispiriting cover story titled “Why We’re Losing the War on Cancer.” The article argued that the “cancer establishment” was wasting time and resources while millions of cancer patients were left waiting for new treatments and a cure for their disease.

While we respected *Fortune’s* analysis, it simply didn’t square with what we were experiencing at the Prostate Cancer Foundation. Here, we saw the best and brightest researchers making real strides in understanding this disease and testing new treatments. We were identifying visionary leaders working relentlessly to remove roadblocks to the development of better treatments and potential cures. And, we were researching treatments and lifestyle changes available to patients right now, helping many live longer.

We felt so strongly, in fact, that we suggested to *Fortune* that they do a follow-up story on the success of the PCF. They took our advice, and the resulting cover story ran in November 2004 under the headline “Beating Cancer.”

**Harnessing Our Power**

At the PCF, we are doing everything in our power to beat cancer. Starting a little more than a decade ago, we turned the “cancer establishment” on its ear, transforming prostate cancer research from a backwater into one of the most important areas of cancer research. We have raised more than $230 million from major donors, corporations, leading brands and individuals to fund prostate cancer research, quickly establishing the PCF as the world’s leading philanthropic source of support for prostate cancer research.

We have funded more than 1,200 prostate cancer research projects at more than 100 institutions worldwide. We have successfully advocated for massive increases in federal funding for prostate cancer research, leveraging your contributions many times over. Moreover, we have continuously worked to clear the barriers to successful prostate cancer research. We have established novel alliances among research institutions and bridged the gap between clinicians in the various medical disciplines, providing them with valuable insight into the research process and gaining their help in speeding prostate
cancer treatments through the development process. We have opened doors to key government officials, providing them with information and support to both rally governmental resources and reduce bureaucratic barriers.

**Achieving Results**

In 2004, we issued the first-ever Report to the Nation on Prostate Cancer, in which 24 prostate cancer thought leaders outlined the state of the art in the diagnosis, treatment and prevention of prostate cancer and laid out a clear agenda for future progress.

The results? We are fighting cancer in meaningful ways. In 2004, an estimated 30,000 men died of prostate cancer, a 26% decrease in prostate cancer deaths from 1993, when the PCF was founded. In 1993, there were five approved drugs for treating prostate cancer. Today there are 13 approved drugs, with many more making their way through the clinical pipeline toward regulatory approval. In 1993, men without prostate cancer didn’t have their prostate specific antigen (PSA) levels routinely checked because the test wasn’t even approved as a preventive screening method. Today, tens of millions of men have their PSA levels checked, allowing physicians to catch prostate cancer at very early stages while also increasing treatment options.

Today, breakthroughs in prostate cancer research seem to happen almost daily, with new reports streaming out about advances in drug development, treatment options, diagnostic capabilities and new lifestyle choices. A recent pinnacle of scientific achievement was reached with the awarding of the 2004 Nobel Prize in Chemistry to Aaron Ciechanover, M.D., D.Sc., a recipient of multiple PCF research grants, to support his award-winning research into the proteasome, which regulates the abundance of key proteins involved in cell survival.
A Team Effort

Indeed, it's a very exciting time to be working on your behalf to find better treatments and an ultimate cure for recurrent prostate cancer. We have been joined in our work by an impressive lineup of supporters, including Major League Baseball, Safeway, eBay, AriZona Beverages, Yahoo!, News Corp., Hugo Boss and many more. We have persuaded the two most populous states in the U.S., New York and California, to include a tax-form check-off to support prostate cancer. We have generated a wave of publicity about our cause with the help of NBC's Today show; our "Act. Like a Man." public service advertising campaign, produced by TBWA\Chiat\Day; and, yes, a cover story in Fortune magazine.

Yet we stay focused on our goal, and for a very good reason: In 2005, an estimated 232,000 men will be diagnosed with prostate cancer. Despite all our achievements to date, another 30,000 men are likely to die from prostate cancer in 2005. Moreover, with the aging of the baby boomer generation, we await a wave of new prostate cancer cases, upwards of 300,000 a year by 2015, and a death rate spiraling up to 50,000 men per year.

These sobering statistics guide us in everything we do. If we are to continue to beat prostate cancer, we will have to marshal far more resources and persuade many more people to join our cause.

That's why we continue to need your help. We're doing everything we possibly can, around the clock, to beat cancer — raising funds, supporting researchers, breaking down barriers, creating alliances— but to do more, we must have your help.

You Must Act

With your generous support, we can fund more of the many worthy research grant requests that arrive at our offices every day. With your help, we will continue to clear the scientific and bureaucratic hurdles that impede progress and cause needless suffering.

This year, we urge you to act and help the Prostate Cancer Foundation continue to beat cancer.

Sincerely,

Michael Milken
Founder and Chairman

Leslie D. Michelson
Vice Chairman and Chief Executive Officer

With your generous support, we can fund more of the many worthy research grant requests that arrive at our offices every day. With your help, we will continue to clear the scientific and bureaucratic hurdles that impede progress and cause needless suffering.
We can’t do it alone. It’s as simple as that. To beat prostate cancer once and for all, we must leverage the talents and resources of thousands of people and institutions around the world. Collaboration, cooperation and teamwork have been hallmarks of the PCF from the start, and they remain important components of the PCF’s ongoing strategy. Our supporters include the people featured in this report—men with prostate cancer, loved ones and others who simply care. Join us.
Cancer of the prostate is the most common non-skin cancer in America. One in six American men will be diagnosed with prostate cancer. A man is 33% more likely to get prostate cancer than a woman is to get breast cancer.

Prostate cancer is a scourge—it attacks millions of men as they age. Last year, 232,000 men received a prostate cancer diagnosis, and the disease took the lives of some 30,000 men, including the famous—Law & Order’s Jerry Orbach, Citigroup’s Walter Wriston, legendary guitarist Johnny Ramone—as well as everyday loved ones—someone’s father, son, brother, friend.

The prostate is no bigger than a walnut, yet it plays a key role in the male reproductive system. Located in a hard-to-reach place between the penis and the bladder, it is unusually susceptible to cancer. Researchers believe the “Western-style” diet of the average American—high in fat but low in fruits and vegetables—may be partly responsible for the high rates of prostate cancer in the U.S. compared with those of other nations. That’s one reason the PCF emphasizes nutrition and lifestyle research. Prostate cancer also has the strongest familial link among all major cancers. Twenty-five percent of prostate cancer patients have a relative with the disease. Race is also a factor—African Americans are 65% more likely to develop prostate cancer compared with Caucasians, and are twice as likely to die from it.

While we still don’t know what causes prostate cancer, we do know that as men get older, their chances of developing the disease rise sharply. With thousands of baby boomers turning 50 every single day, the cohort of men who will get prostate cancer is growing rapidly. So the PCF considers itself to be in a race against time to develop better treatments and a cure for recurrent prostate cancer as soon as possible.

### PROSTATE CANCER STATUS UPDATE

<table>
<thead>
<tr>
<th>Age</th>
<th>Likelihood</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–39</td>
<td>less than 1%</td>
</tr>
<tr>
<td>40–59</td>
<td>3%</td>
</tr>
<tr>
<td>60–79</td>
<td>14%</td>
</tr>
<tr>
<td>Overall</td>
<td>17%</td>
</tr>
</tbody>
</table>

“I’ve never seen a harder-working team than the people at the PCF. Their commitment to winning the fight against this disease is matched only by their desire to save lives.”
<table>
<thead>
<tr>
<th>NAME</th>
<th>Joe Torre</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE</td>
<td>64</td>
</tr>
<tr>
<td>OCCUPATION</td>
<td>Four-time World Series champion and Manager, New York Yankees</td>
</tr>
<tr>
<td>PCF CONNECTION</td>
<td>An influential leader in the PCF’s Home Run Challenge, Joe is a spokesman, public advocate and role model for the PCF.</td>
</tr>
<tr>
<td></td>
<td>“New treatments and early detection are saving lives, but the fight won’t be over until we find a cure. The PCF is doing more than any other group to see to it that we win this battle.”</td>
</tr>
</tbody>
</table>
In the 11 years of the PCF’s existence, leading-edge prostate cancer diagnosis, treatment and prevention have come a long way. Today, there are two primary screening methods for prostate cancer: digital rectal exam and the PSA blood test. In addition, a battery of treatment options are available including removal of the prostate (radical prostatectomy) and radiation treatment (external beam or brachytherapy) for localized prostate cancer. Treatment options for advanced or metastatic prostate cancer include hormone therapy and chemotherapy. Currently, there are 13 approved drugs to treat prostate cancer, more than double the number available when the PCF opened its doors.

Moreover, there are scores of new drugs and novel treatment options in various stages of research and development for the treatment and management of prostate cancer, many of them funded by the PCF. The PCF is committed to bringing new drugs and treatment options through the regulatory process and into the hands of practicing physicians as quickly as possible.

The PCF exists for a single purpose: to drive research to find better treatments and a cure for recurrent prostate cancer. In its first 11 years, the PCF has raised more than $230 million, making it the world’s largest source of philanthropic support for prostate cancer research. By keeping its expenses low, the PCF has been able to devote 78 cents of every dollar raised to research, making it one of the most efficient medical charities in the country.

To date, the PCF has awarded grants to more than 1,200 researchers at more than 100 institutions worldwide. Last year, the PCF awarded grants to 25 researchers worldwide. Many of the proposals submitted were highly worthy of funding, yet were turned down simply due to lack of funds. The PCF is committed to working with its donors and partners to raise enough funds so that every worthy applicant receives funding.
“I cannot tell you what a difference the PCF has made in the lives of men and their families. After working in this field for 45 years, I’m excited about what the future holds.”
<table>
<thead>
<tr>
<th>NAME</th>
<th>Donald S. Coffey, Ph.D.</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE</td>
<td>72</td>
</tr>
<tr>
<td>OCCUPATION</td>
<td>Professor of urology, oncology, pharmacology and molecular sciences and pathology, The Johns Hopkins University School of Medicine</td>
</tr>
<tr>
<td>PCF CONNECTION</td>
<td>The “grandfather” of prostate cancer research, Dr. Coffey was the first scientist to join forces with the PCF and has been a strategic guide to the Foundation ever since.</td>
</tr>
</tbody>
</table>

“For the first time in my life, I honestly think we can cure prostate cancer. The PCF is largely responsible for that.”
Prostate cancer also has the strongest familial link among all major cancers. Twenty-five percent of prostate cancer patients have a relative with the disease. Race is also a factor—African Americans are 65% more likely to develop prostate cancer compared with Caucasians, and are twice as likely to die from it.

The PCF employs a novel “fast-track” approach to funding scientific research. Rather than requiring applicants to spend valuable time crafting elaborate funding requests only to have them wait months for a decision, the PCF has greatly streamlined the process, requiring only a five-page application and providing a response within 90 days. This approach has enabled the PCF to bring prostate cancer research quickly up to speed and has resulted in numerous breakthrough research achievements.

Recent PCF achievements include:

- Groundbreaking work with recent Nobel Prize winner Aaron Ciechanover, M.D., D.Sc., for his work in illuminating the significance of the proteasome, a cellular function that regulates the destruction of unneeded cell proteins. Dr. Ciechanover has received multiple research grants from the PCF to study the application of his research to prostate cancer.

- The proteasome is the target of Millennium’s Velcade (bortezomib), which is currently in clinical trials for the treatment of prostate cancer and has already been approved for the treatment of multiple myeloma. The PCF provided crucial early funding to support the initial development of Velcade.

- Abbott Laboratories’ 2004 submission of an application to market Xinlay (atrasentan) for the treatment of metastatic hormone-refractory prostate cancer, an advanced stage of prostate cancer that no longer responds to hormone treatment and has spread to other parts of the body, particularly the bones. The PCF provided initial funding for research at The Johns Hopkins University into atrasentan, an endothelin-1 receptor antagonist, which was proven to slow the growth of prostate cancer cells in the laboratory and in animal studies. Additional PCF-supported research showed that the agent attacks prostate cancer in bone, laying the foundation for the successful clinical trials that followed and Abbott’s application for permission to market the drug.
“The PCF is doing a great job at harnessing more of society’s resources to defeat this deadly disease. Safeway is proud to support the extraordinary work of the PCF.”
<table>
<thead>
<tr>
<th>NAME</th>
<th>Steve Burd</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE</td>
<td>55</td>
</tr>
<tr>
<td>OCCUPATION</td>
<td>Chairman and CEO, Safeway Inc.</td>
</tr>
<tr>
<td>PCF CONNECTION</td>
<td>Under Steve’s leadership, Safeway has become a leader of community causes, including prostate cancer, breast cancer, hunger relief and education.</td>
</tr>
</tbody>
</table>

“Prostate cancer is the most common cancer in America, attacking families in communities everywhere. Since 2001, Safeway has raised more than $8 million for prostate cancer research, because our vision has always been to give back to the communities we serve.”
Progress toward the improvement of clinical trials through the development of new clinical end points for studying the effectiveness of prostate cancer therapies. In 2004, the FDA convened the first-ever workshop to consider new alternatives for measuring the effectiveness of potential prostate cancer drugs. Currently, most prostate cancer drugs require an increase in survival time to obtain FDA approval; it can take five to ten years to gather enough evidence to support regulatory approval. Through the persistence of the PCF and many others, the FDA is now looking at alternatives such as “surrogate markers” (information about changes in the body that are believed to provide insight into the progress or remission of prostate cancer) to predict the efficacy of a new drug. One such highly promising surrogate marker, the observed change in PSA levels in men with prostate cancer, has been heavily studied with the support of the PCF. The PCF is continuing to work in concert with researchers and the FDA to identify new clinical end points and speed the drug development and approval process.

Issuance of the inaugural Report to the Nation on Prostate Cancer, a groundbreaking new source of leading-edge prostate cancer information geared to healthcare professionals involved in the care of prostate cancer patients, including urologists, medical oncologists and radiation oncologists. The 96-page Report, developed in conjunction with WebMD/Medscape, the leading provider of online healthcare education, offers a comprehensive overview of the state of the art in prostate cancer diagnosis, treatment and prevention, and was authored by 24 of the world’s leading experts on the subject. Chapters range from detection and diagnosis to chemotherapeutic options, emerging therapies, nutrition and prevention strategies, and management of the side effects of prostate cancer therapy. The purpose of the Report is to supply clinicians with a clearer understanding of how to work together to provide optimal care to patients with prostate cancer.

Each year, the PCF hosts a Scientific Retreat for more than 350 leading prostate cancer research scientists, biopharmaceutical executives and government policy makers. It is now the world’s leading annual scientific gathering focused on the prevention, treatment and cure of prostate cancer.
“There’s nobody else, no other entity in the world, that matches the PCF’s dedication and creativity in raising money and finding cures.”
NAME: Wade F. B. Thompson

AGE: 64

OCCUPATION: Chairman, President and CEO, Thor Industries, Inc.

PCF CONNECTION: A key PCF supporter and a survivor of prostate cancer, melanoma and colon cancer, Wade is dedicating his life to defeating cancer.

“Despite exercise, a good diet and annual medical checkups, prostate cancer can strike anybody, at any time. We all should be thankful to the PCF for the progress they have made towards finding a cure.”
The PCF, with the support of its Pharmaceutical Industry Roundtable, distributed more than 17,000 copies to treating physicians around the U.S. and has made it available for free online. The WebMD/Medscape Web site tracked more than 45,000 unique visits to the Report in just over four months. In addition, over 4,000 Continuing Medical Education (CME) credits have been issued.

We can’t do it alone. It’s as simple as that. To beat prostate cancer once and for all, the PCF must leverage the talents and resources of thousands of people and institutions around the world. Collaboration, cooperation and teamwork have been hallmarks of the PCF from the start, and they remain important components of the PCF’s ongoing strategy.

Examples of the PCF’s recent collaborative efforts include:

- **Annual Scientific Retreat:** Each year, the PCF hosts a Scientific Retreat for more than 350 leading prostate cancer research scientists, biopharmaceutical executives and government policy makers. It is now the world’s leading annual scientific gathering focused on the prevention, treatment and cure of prostate cancer. The retreat features three days of scientific presentations, poster sessions and intense dialogue about clinical data, new discoveries, emerging treatment strategies and policies to accelerate drug discovery and development.

The PCF’s 11th Annual Retreat, held in October 2004 in Lake Tahoe, Nevada, featured many noteworthy presentations, including several involving the nutritional aspects of prostate cancer prevention and treatment. Meir Stampfer, M.D., of the Harvard School of Public Health, presented preliminary findings of a study currently underway, noting that when men with a particular genotype had an increased intake of antioxidants, they reduced their risk of prostate cancer to 50% below that of...
“My father was diagnosed with prostate cancer in 1996. We were devastated as a family and scared. We knew this was not just a disease for men but for everyone in the family.”
<table>
<thead>
<tr>
<th><strong>NAME</strong></th>
<th>Beth Kobliner Shaw</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AGE</strong></td>
<td>40</td>
</tr>
<tr>
<td><strong>PCF CONNECTION</strong></td>
<td>After the diagnosis of her father, Beth was instrumental in bringing about a 25-fold increase in government funding, ensuring the advancement of prostate cancer research.</td>
</tr>
</tbody>
</table>

“Finding the PCF was like finding an oasis. They’re wonderful people who knew what we were going through — they helped us tackle one of the most difficult situations.”
June M. Chan, Sc.D., of the University of California at San Francisco, presented data gleaned from the Health Professionals Follow-Up Study showing that increased consumption of lycopene can reduce the risk of disease progression in men who have already been diagnosed with prostate cancer.

Further, June M. Chan, Sc.D., of the University of California at San Francisco, presented data gleaned from the Health Professionals Follow-Up Study showing that increased consumption of lycopene can reduce the risk of disease progression in men who have already been diagnosed with prostate cancer. Among men followed by the study, those who consumed an extra two servings per week of lycopene-rich cooked tomato products after prostate cancer diagnosis reduced their risk of disease progression by nearly 20%.

Clinical Research Consortium: Eight leading cancer research centers are collaborating under the auspices of the PCF to test and develop promising prostate cancer therapies. By agreeing to eliminate institutional barriers and to conduct fast-track clinical testing, the consortium provides the pharmaceutical industry with an ideal platform for speeding prostate cancer drugs to market. The eight member institutions are Cedars-Sinai Medical Center (Los Angeles); Dana-Farber Cancer Institute (Boston); The Johns Hopkins University (Baltimore); M.D. Anderson Cancer Center (Houston); Memorial Sloan-Kettering Cancer Center (New York); the UCSF Comprehensive Cancer Center (San Francisco); the University of Michigan Medical Center (Ann Arbor); and the University of Wisconsin Comprehensive Cancer Center (Madison).

Pharmaceutical Industry Roundtable: The world’s leading pharmaceutical companies play a crucial role in beating prostate cancer. To engage them most efficiently and usefully, the PCF has formed an Industry Roundtable designed to reduce barriers to the optimal treatment of prostate cancer; promote and conduct prostate cancer research; advocate for accelerated drug
“By supporting the PCF, you have joined the fight of your life—we must and can win!”
<table>
<thead>
<tr>
<th><strong>NAME</strong></th>
<th>Aaron Ciechanover, M.D., D.Sc.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AGE</strong></td>
<td>58</td>
</tr>
</tbody>
</table>
| **OCCUPATION**    | Professor, Vascular and Tumor Biology  
Research Center; Director, The Rappaport Faculty of Medicine and Research Institute, Technion, Israel Institute of Technology |
| **PCF CONNECTION**| Since 2000, the PCF has funded Dr. Ciechanover through its Israel Initiative. In 2004, he received a Nobel Prize for his work on the significance of the proteasome, which regulates the destruction of unneeded cell proteins. |
approvals; and support the development of assertive treatment guidelines and interdisciplinary medical education. Formed in 2004, the charter members of the Roundtable are Abbott Laboratories, Bristol-Myers Squibb, Novartis and Sanofi-Aventis. The Roundtable’s first major achievement was the publication and distribution of the Report to the Nation on Prostate Cancer in 2004.

The PCF is grateful for the wide-ranging support it receives for its work to beat prostate cancer. Each year, thousands of people give generously of their time and money to support the PCF’s relentless efforts to find better treatments and a cure for recurrent prostate cancer.

Even with all that help, it’s still not enough. The PCF is unable to fund all of the outstanding grant requests it receives and must turn down researchers eager to probe the complexities of prostate cancer and develop innovative new treatments. Every day, the PCF reaches out to new individuals and organizations to join the fight.

In 2004, the PCF was pleased to welcome the following new supporters to the team:

- **Callaway Golf:** In September, Callaway sponsored a “$1 Million Dollar Putt” contest outside the New York Stock Exchange. As hundreds of people watched on the street, celebrities competed to sink a 100-foot putt, with the proceeds going to the PCF.

- **eBay:** Over the summer of 2004, eBay hosted “Because You Love Him,” an online auction of more than 350 items, including one-of-a-kind offerings such as two hours with Magic Johnson; an afternoon with Arnold Palmer; dinner with Jennifer Hawkins, Miss Universe 2004; lunch with platinum recording artist Avril Lavigne; tennis with Donald Trump; and a visit to the set of the hit TV show Las Vegas with James Caan. The auction raised more than $200,000 for prostate cancer research and will become an annual event.
“The PCF has been a driving force in expanding and accelerating prostate cancer research. The PCF’s research and focus on diet is very important. I’m convinced of that!”
<table>
<thead>
<tr>
<th>NAME</th>
<th>Nelson Peltz</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE</td>
<td>62</td>
</tr>
<tr>
<td>OCCUPATION</td>
<td>Chairman and CEO, Triarc Companies, Inc.</td>
</tr>
<tr>
<td>PCF CONNECTION</td>
<td>A leader in the business community and a recognized philanthropist, Nelson has brought his considerable skills to the PCF board of directors.</td>
</tr>
</tbody>
</table>

“The number and caliber of research scientists dedicated to prostate cancer has increased dramatically over the last 12 years. I credit that primarily to the PCF.”
Safeway, the food and drug retailer, raised $3.3 million for prostate cancer research in 2004 through point-of-purchase promotions at more than 15,000 checkout stands in all 1,600 Safeway stores in the U.S.

- **Esquire**: This leading men’s magazine has selected the PCF as its official charity. It is supporting the cause through a prostate cancer advertorial and by encouraging leading men’s fashion companies and retailers to support prostate cancer research.

- **GNC**: In June, this leading specialty retailer of vitamin, mineral, herbal and sports nutrition supplements joined the fight against prostate cancer with in-store promotions and fund-raising, blue-ribbon prostate cancer awareness pins and employee incentives to raise money for prostate cancer research at its more than 5,000 retail outlets throughout the U.S.

- **Hugo Boss**: This maker of fine men’s and women’s clothing hosted two special in-store “True-Blue Night” events in New York City and Beverly Hills, with a portion of the proceeds going to benefit the PCF. In addition, during the months of June and September in honor of Father’s Day and Prostate Cancer Awareness Month, respectively, Hugo Boss donated a percentage of sales to the PCF.

- **Ferragamo**: As a participant in the “Blue for Men” campaign, legendary fashion purveyor Ferragamo donated 15% of select blue tie purchases during the month of September to the PCF.

The Prostate Cancer Foundation wouldn’t be where it is today — the world’s leading source of philanthropic support for prostate cancer research — without its longtime supporters. Highlights of their efforts in 2004 included:

- **A Night to Remember**: The Niebaum-Coppola Estate Winery in Napa hosted Marvin Shanken’s 12th annual fund-raiser for the PCF, raising nearly $800,000 for prostate cancer research.

- **Safeway**: The food and drug retailer raised $3.3 million for prostate cancer research in 2004 through point-of-purchase promotions at more than 15,000 checkout stands in all 1,600 Safeway stores in the U.S. Employees also participated in internal fund-raising drives to boost proceeds.
“I learned about the PCF after doing a great deal of research and investigation. I decided this was the one charity where I wanted to consolidate all my energy and time.”
<table>
<thead>
<tr>
<th>NAME</th>
<th>Marvin R. Shanken</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE</td>
<td>62</td>
</tr>
<tr>
<td>OCCUPATION</td>
<td>Chairman, M. Shanken Communications Inc.</td>
</tr>
</tbody>
</table>

**PCF CONNECTION**  
Marvin created and produces the annual event, *A Night to Remember*, which in 2004 raised more than $800,000 for prostate cancer research. Since inception, Marvin’s events have raised more than $4 million for the PCF.

“Prostate cancer is perhaps the most serious disease facing all men. And, as a man and publisher of men’s magazines, this subject is near and dear to my heart, which is why I support and tell all my friends to support the PCF.”
- **Major League Baseball:** Once again, baseball went to bat for prostate cancer research during the Home Run Challenge over Father’s Day. Everyone from groundskeepers to team owners donned blue wristbands and watched as sluggers belted 132 home runs during the fund-raising week, generating $2 million to support the work of the PCF.

- **Benefit at Bighorn Pro-Am:** Founded in 1998 with the help of pro golfer Jim Colbert after he was diagnosed with prostate cancer, this pro-am tournament joins current players on the Champions Tour with PCF supporters for a day on one of the country’s premier golf courses, in Palm Desert, California. Pro golfers who have participated at Bighorn include Bruce Fleisher, Hale Irwin, Gary McCord, Jim Thorpe, Jay Siegel and Lee Trevino.

- **Carl H. Lindner Pro-Am Invitational Tennis Tournament:** Hosted by Donald Trump at his legendary Mar-a-Lago Club in Palm Beach, Florida, this round-robin tennis tournament and fund-raiser draws a star-studded field, including tennis pros such as Chris Evert, Jimmy Connors, Mats Wilander, Cliff Drysdale, Petr Korda, Stan Smith and Fred Stolle.

- **Indian Wells Tennis Tournament:** Held in conjunction with the Pacific Life Open, this round-robin tennis tournament pairs amateurs and celebrities with some of the best players in tennis. Pros Luke and Murphy Jensen, John Lloyd, Jeff Tarango, Jonas Bjorkman and Eddie Dibbs have taken part in this benefit for the PCF.

- **Gourmet Games:** Blending the PCF’s advocacy of a cancer-fighting diet with fund-raising, the PCF hosts “Gourmet Games” in Los Angeles and Seattle, featuring both wine and food tastings and contests between teams of celebrities and VIPs, challenging participants’ tastes and perceptions of food in a fun and informative evening.
“The PCF is a first-class organization that gives people hope. They are real people who are helping provide answers and a cure for a disease that affects men everywhere.”
<table>
<thead>
<tr>
<th>NAME</th>
<th>Rosey Grier</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGE</td>
<td>72</td>
</tr>
<tr>
<td>OCCUPATION</td>
<td>Former NFL Star, New York Giants and Los Angeles Rams</td>
</tr>
<tr>
<td>PCF CONNECTION</td>
<td>A member of the PCF board of directors, Rosey has been a strong supporter from the beginning, working hard to create awareness of prostate cancer throughout African American communities.</td>
</tr>
</tbody>
</table>

“As bad as this disease is for Caucasians, it’s much worse for African Americans. But don’t give up, the PCF is bringing everyone together to find a cure in our lifetimes.”
RESEARCH AWARDS

Albert Einstein
College of Medicine
$75,000
Nicole B. Schreiber-Agus, Ph.D.

Assaf Harofe Medical Center (Israel)
$150,000
Amnon Zisman, M.D.

Bar-Ilan University (Israel)
$150,000
Nicole B. Schreiber-Agus, Ph.D.

Baylor University
$3,300,000
Jacques Banchereau, Ph.D.

Ben-Gurion University of the Negev (Israel)
$375,000
Ron N. Apte, Ph.D.

Brandeis University
$250,000
Lizbeth Hedstrom, Ph.D.

Burnham Institute
$1,786,000
Wadih Arap, M.D., Ph.D.

California Institute of Technology
$450,000
Raymond J. Deshaies, Ph.D.
Huabao Guo, Ph.D.
Alexander J. Varshavsky, Ph.D.

California Pacific Medical Center
$100,000
Robert J. Debs, M.D.

Cancer Institute of New Jersey
$75,000
Robert S. DiPaola, M.D.

Cantonal Hospital St. Gall (Switzerland)
$75,000
Marcus Groettrup, Ph.D.

Case Western Reserve University
$350,000
Sanford Markowitz, M.D., Ph.D.
Bingcheng Wang, Ph.D.

Cedars-Sinai Medical Center
$2,095,000
David B. Agus, M.D.
H. Phillip Koeffler, M.D.
Isett Laux, Ph.D.

Cleveland Clinic Foundation
$2,095,000
Katerina Gurova, Ph.D.
Edward Plow, Ph.D.

Cold Spring Harbor Laboratory
$100,000
Robert Lucito, Ph.D.

Columbia University
$2,129,500
Allen Pavilion Presbyterian Hospital
Carl A. Olsson, M.D.
Atchley Pavilion
Ralph Buttyan, Ph.D.

College of Physicians and Surgeons
Paul B. Fisher, Ph.D.
Aaron E. Katz, M.D.
Nickolas Papadopoulos, Ph.D.

Columbia Presbyterian Medical Center
Daniel Petrylak, M.D.

Cornell University
$4,100,000
Beatrice S. Knudsen, M.D., Ph.D.
David M. Nanus, M.D.

Dartmouth-Hitchcock Medical Center
$75,000
Marc S. Ernstoff, M.D.

Duke University
$1,050,000
Phillip Febbo, M.D.
Eli Gilboa, Ph.D.
Susan Halabi, Ph.D.
Michael C. Pirrung, Ph.D.
David T. Price, M.D.
Johannes W. Vieweg, M.D.

Eastern Virginia Medical School
$175,000
George L. Wright Jr., Ph.D.

Emory University
$250,000
Wayne Harris, M.D.
John A. Petros, M.D.

Erasmus University (Netherlands)
$250,000
Jan Trapman, Ph.D.
Gert J. van Steenbrugge, Ph.D.

Fred C. Hutchinson Cancer Research Center
$2,680,000
Peter S. Nelson, M.D.
Elaine A. Ostrander, Ph.D.
Janet L. Stanford, Ph.D.

Georgetown University
$1,000,000
Lombardi Cancer Center
Edward P. Gelmann, M.D.
Robert L. Martuza, M.D.
Renxiao Wang, Ph.D.
Shaomeng Wang, Ph.D.
<table>
<thead>
<tr>
<th>Institution</th>
<th>Amount</th>
<th>Collaborators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hadassah University (Israel)</td>
<td>$485,000</td>
<td>Rachel Bar-Shavit, Ph.D. Eithan Galun, M.D., Ph.D. Amnon Peled, Ph.D. Eli Pikarsky, M.D., Ph.D. Israel Vlodavsky, Ph.D.</td>
</tr>
<tr>
<td>Institution</td>
<td>Amount</td>
<td>Investigators</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>------------</td>
<td>---------------------------------------------------</td>
</tr>
<tr>
<td>Mayo Clinic and Foundation</td>
<td>$500,000</td>
<td>Lorraine A. Fitzpatrick, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>John C. Morris, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Donald J. Tindall, Ph.D.</td>
</tr>
<tr>
<td>Memorial Sloan-Kettering Cancer Center</td>
<td>$14,535,000</td>
<td>David B. Agus, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>William R. Fair, M.D., F.A.C.S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>George Farmer, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Leonard P. Freedman, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zvi Fuks, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Polly Gregor, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adriana Haimovitz-Friedman, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Warren D.W. Heston, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>William Kevin Kelly, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Philip O. Livingston, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paul A. Marks, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Michael R. McDevitt, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Nanus, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neal Rosen, M.D., Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Michael Sadelain, M.D., Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peter T. Scardino, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David A. Scheinberg, M.D., Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Howard I. Scher, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>George Sgouros, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Shaffer, M.D., Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moshe Shike, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Susan F. Slovin, M.D., Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Peter Smith-Jones, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jedd D. Wolchok, M.D., Ph.D.</td>
</tr>
<tr>
<td>Menzies Centre for Population Health Research (Australia)</td>
<td>$50,000</td>
<td>David A. Mackey, M.D.</td>
</tr>
<tr>
<td>Mount Sinai School of Medicine</td>
<td>$275,000</td>
<td>Michael J. Droller, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Irwin H. Gelman, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>John A. Martignetti, M.D., Ph.D.</td>
</tr>
<tr>
<td>New York Medical College</td>
<td>$150,000</td>
<td>Cancer Research Institute</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sophie Chen, Ph.D.</td>
</tr>
<tr>
<td>New York University</td>
<td>$430,000</td>
<td>Maarten C. Bosland, D.V.Sc., Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Herbert Lepor, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ian J. Mohr, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Samir Taneja, M.D.</td>
</tr>
<tr>
<td>Skirball Institute of Biomolecular Medicine</td>
<td>$475,000</td>
<td>Gerald P. Murphy, M.D., D.Sc.</td>
</tr>
<tr>
<td>Northwest Hospital</td>
<td>$475,000</td>
<td>Wade Bushman, M.D., Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zhou Wang, Ph.D.</td>
</tr>
<tr>
<td>Ohio State University</td>
<td>$100,000</td>
<td>M. Guilt Wiensjes, Ph.D.</td>
</tr>
<tr>
<td>Oregon Health Sciences University</td>
<td>$100,000</td>
<td>Ron G. Rosenfeld, M.D.</td>
</tr>
<tr>
<td>Preventive Medicine Research Institute</td>
<td>$500,000</td>
<td>Dean Ornish, M.D.</td>
</tr>
<tr>
<td>Rabin Medical Center (Israel)</td>
<td>$50,000</td>
<td>Avishay Selia, M.D.</td>
</tr>
<tr>
<td>Rockefeller University</td>
<td>$500,000</td>
<td>Robert G. Roeder, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Strang Cancer Research Laboratory</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Martin Lipkin, M.D.</td>
</tr>
<tr>
<td>Roger Williams Medical Center</td>
<td>$100,000</td>
<td>Richard P. Junghans, Ph.D., M.D.</td>
</tr>
<tr>
<td>Salk Institute for Biological Studies</td>
<td>$760,050</td>
<td>Ronald M. Evans, Ph.D.</td>
</tr>
<tr>
<td>San Diego Cancer Research</td>
<td>$75,000</td>
<td>R. Michael Williams, M.D., Ph.D.</td>
</tr>
<tr>
<td>Scripps Research Institute</td>
<td>$975,000</td>
<td>Ruben A. Abagyan, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>K.C. Nicolaou, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prabhakar Triprunaneni, M.D.</td>
</tr>
<tr>
<td>Sheba Medical Center (Israel)</td>
<td>$150,000</td>
<td>Gideon Rechavi, M.D., Ph.D.</td>
</tr>
<tr>
<td>Stanford University</td>
<td>$1,225,000</td>
<td>Gerald R. Crabtree, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>David Feldman, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Calvin J. Kuo, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>John E. McNeal, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Donna M. Pehl, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thomas A. Stamey, M.D.</td>
</tr>
<tr>
<td>St. Louis University</td>
<td>$75,000</td>
<td>William S.M. Wold, Ph.D.</td>
</tr>
<tr>
<td>State University of New York</td>
<td>$112,500</td>
<td>Downstate Medical School</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jack Mydlo, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stony Brook</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Victor I. Romanov, Ph.D.</td>
</tr>
<tr>
<td>Technion, Israel Institute of Technology (Israel)</td>
<td>$625,000</td>
<td>Ami Aronheim, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Aaron Ciechanover, M.D., D.Sc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fuad Fares, D.Sc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ehud Keinan, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gera Neufeld, Ph.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Israel Vlodavsky, Ph.D.</td>
</tr>
</tbody>
</table>
Tel-Aviv University (Israel)
$400,000
Zvi Fishelson, Ph.D.
Sara Lavi, Ph.D.
Ada Rephaeli, Ph.D.
Ilan Tsarfaty, Ph.D.
Sourasky Medical Center
Ben-Zion Katz, Ph.D.
Avi Orr-Urtreger, M.D., Ph.D.

University of California
$16,465,068
Lawrence Livermore
National Laboratory
Christine Hartmann Siantar, Ph.D.
University of California, Berkeley
James P. Allison, Ph.D.
Carolyn Bertozzi, Ph.D.
Arthur A. Hurwitz, Ph.D.
David H. Raulet, Ph.D., B.S.
Peter G. Schultz, Ph.D.
David E. Wemmer, Ph.D.
University of California, Davis
Shing-Jien Kung, Ph.D.
University of California, Los Angeles
Arie S. Beldegrun, M.D.
Michael F. Carey, Ph.D.
Rowan T. Chlebowski, M.D., Ph.D.
Pinchas Cohen, M.D.
Jean B. deKernion, M.D.
Purnima Dubey, Ph.D.
Sanjiv S. Gambhir, M.D., Ph.D.
David Heber, M.D., Ph.D.
Harvey R. Herschman, Ph.D.
Michael E. Jung, Ph.D.
Jay R. Lieberman, M.D.
Carl W. Miller, Ph.D.
Ayyappan K. Rajasekaran, Ph.D.
Robert Reiter, M.D.
Peter Rosen, M.D.
Kathleen M. Sakamoto, M.D.
Charles L. Sawyer, M.D.
Marc A. Seltzer, M.D.
Ke Shuai, Ph.D.
Peter Tontonoz, M.D., Ph.D.
Owen W. Witte, M.D.
Hong Wu, M.D., Ph.D.
University of California, San Diego
Dennis A. Carson, M.D.
Randolph D. Christen, M.D.
Lawrence S.B. Goldstein, Ph.D.
Michael Karin, Ph.D.
Michael G. Rosenfeld, Ph.D.
Helen P. Tighe, Ph.D.
Maurizio Zanetti, M.D.

University of Chicago
$425,000
Douglas K. Bishop, Ph.D.
Carrie W. Rinker-Schaeffer, Ph.D.
Mitchell H. Sokoloff, M.D.

University of Colorado
$730,000
L. Michael Glode, M.D.
William E. Huffer, M.D.
Andrew S. Kraft, M.D.
Gary J. Miller, M.D., Ph.D.

University of Connecticut
$100,000
Pramod Srivastava, Ph.D.

University of Edinburgh (Scotland)
$75,000
Fouad K. Habib, Ph.D.
University of Helsinki (Finland)  $200,000
Institute of Biomedicine
Olli A. Janne, M.D., Ph.D.

University of Illinois  $50,000
Nissum Hay, Ph.D.

University of Innsbruck (Austria)  $100,000
Zoran Culig, M.D.

University of Iowa  $75,000
George Weiner, M.D.

University of Kentucky  $100,000
Vivek M. Rangnekar, Ph.D.

University of Maryland  $200,000
Natsheh Kyprianou, Ph.D.
Yun Qiu, Ph.D.

University of Massachusetts  $325,000
Michael R. Green, M.D., Ph.D.
Shuk-Mei Ho, Ph.D.
Mani Menon, M.D.

University of Michigan  $3,275,000
Arun Chinnaiyan, M.D., Ph.D.
Mark Day, Ph.D.
Evan T. Keller, D.V.M., Ph.D.
Donna Livant, Ph.D.
Kenneth J. Pienta, M.D.
Martin G. Sandra, M.D.
Shaomeng Wang, Ph.D.

University of Missouri, Columbia  $75,000
Valeri V. Mossine, Ph.D.

University of Munich (Germany)  $100,000
Bernd Gansbacher, M.D.

University of North Carolina, Chapel Hill  $250,000
David Ornstein, M.D.
Terry Van Dyke, Ph.D.

University of Pennsylvania  $400,000
Mark I. Greene, M.D., Ph.D.
Wistar Institute
George C. Prendergast, Ph.D.

University of Pittsburgh  $2,275,000
Michael J. Becich, M.D., Ph.D.
Barbara A. Foster, Ph.D.
John Gilbertson, M.D.
Susan L. Greenspan, M.D.
Candace S. Johnson, Ph.D.
Joel B. Nelson, M.D.
Donald L. Trump, M.D.
Janey Whalen, Ph.D.

University of Rochester  $400,000
Chawnshang Chang, Ph.D.
Edward Messing, M.D.

University of Southern California  $200,000
Gerhard A. Coetzee, Ph.D.
Donald G. Skinner, M.D.

University of Tampere (Finland)  $300,000
Tapio Visakorpi, M.D., Ph.D.

University of Tennessee  $150,000
Jeffrey Gingrich, M.D.

University of Texas  $11,342,000
Health Science Center at San Antonio
Susan Padalecki, Ph.D.

M.D. Anderson Cancer Center
Wadih Arap, M.D., Ph.D.
Danai Daliani, M.D.
John DiGiovanni, Ph.D.
Isaiah J. Fidler, D.V.M., Ph.D.
Sue-Hwa Lin, Ph.D.
Christopher J. Logothetis, M.D.
David J. McConkey, Ph.D.
Timothy J. McDonnell, M.D., Ph.D.
Nora M. Navone, M.D., Ph.D.
Christos N. Papandreou, M.D., Ph.D.
Renata Pasqualini, Ph.D.
Dean G. Tang, M.D., Ph.D.
Andrew C. von Eschenbach, M.D.
Christopher G. Wood, M.D.
Southwestern Medical Center, Dallas
Jerry W. Shay, Ph.D.

University of Toronto (Canada)  $350,000
Sunnybrook Health Science Center
Shoukat Dedhar, Ph.D.
Robert S. Kerbel, Ph.D.

University of Utah, Health Sciences Center  $100,000
Arthur R. Brothman, Ph.D.

University of Virginia  $3,825,000
Leland W.K. Chung, Ph.D.
Thomas A. Gardiner, M.D.
Theresa Guise, M.D.
Deborah Lannigan, Ph.D.
Charles E. Myers Jnr., M.D.
J. Thomas Parsons, Ph.D.
Fraydoon Rastinejad, Ph.D.
Mitchell Sokoloff, M.D.
Michael J. Weber, Ph.D.

University of Washington  $7,873,220
Arthur Caperton, Ph.D.
Martin A. Cheever, M.D.
Leroy Hood, M.D., Ph.D.
Gail Jarvik, M.D.
Paul H. Lange, M.D.
Robert L. Vessella, Ph.D.
University of Wisconsin
$4,175,000
David A. Boothman, Ph.D.
Chawnshang Chang, Ph.D.
David F. Jarrard, M.D.
Douglas G. McNeel, M.D., Ph.D.
George Wilding, M.D.
Donald T. Witiak, Ph.D.

Urological Sciences Research Foundation
$100,000
Leonard S. Marks, M.D.

Utah State Cancer Registry
$183,420
Janet Stanford, M.D.

Vanderbilt University
$350,000
Sam Chang, M.D.
Robert Matusik, Ph.D.
Joseph A. Smith Jr., M.D.

Veterans Administration
$4,622
Patricia Cornett, M.D.

Volcani Center (Israel)
$180,000
Mark Pines, Ph.D.

Vrije Universiteit medisch centrum (Netherlands)
$300,000
Tanja D. de Gruijl, Ph.D.

Walter Reed Army Medical Center
$50,000
David G. McLeod, M.D., J.D.

Washington University
$3,439,166
William J. Catalona, M.D.
Mark L. Day, Ph.D.
Helen Donis-Keller, Ph.D.
Steven F. Dowdy, Ph.D.
Peter A. Humphrey, M.D., Ph.D.
Jeffrey Milbrandt, M.D., Ph.D.
Nobuyuki Oyama, M.D., Ph.D.
Timothy L. Ratliff, Ph.D.
Brian K. Suarez, Ph.D.

Wayne State University
$350,000
Michael L. Cher, M.D.
Kenneth V. Honn, Ph.D.
Harper Hospital
J. Edson Pontes, M.D.

Weizmann Institute of Science (Israel)
$1,625,000
Avri Ben-Ze’ev, Ph.D.
Hadassa Degani, Ph.D.
Zelig Eshhar, Ph.D.
Benjamin Geiger, Ph.D.
Yitzhak Koch, Ph.D.
Yoram Salomon, Ph.D.
Rony Seger, Ph.D.
Yehezkel Shai, Ph.D.
Yosef Shaul, Ph.D.
David Wallach, Ph.D.
Yosef Yarden, Ph.D.
Yehiel Zick, Ph.D.

Yale University
$200,000
Craig M. Crews, Ph.D.
The Prostate Cancer Foundation would like to thank everyone who has donated to the foundation. We gratefully acknowledge the following individuals, foundations, corporations and others who have given at least $5,000 between our inception, in 1993, and December 31, 2004.

**2004 DONOR LIST**

**Founder (>$50 Million)**
- Milken Family Foundation

**Founder’s circle ($2,000,000 – $49,999,999)**
- Anonymous (1)
- David Hamilton Koch
- Carl and Edyth Lindner
- Lowell and Sandy Milken
- Michael and Lori Milken
- News Corporation Foundation
- Stewart and Lynda Resnick
- Safeway, Inc.
- Stephen and Elaine Wynn

**Leadership Circle ($1,000,000 – $1,999,999)**
- Anonymous (5)
- Leon and Debra Black
- Jamie B. Coulter
- The Craig and Susan McCaw Foundation
- Charles F. Dolan
- William L. Edwards
- Andrew S. Grove
- Sidney Kimmel
- Thomas H. and Ann Tenenbaum Lee
- The Lincy Foundation
- Kerry Parker
- Nelson and Claudia Peltz/Triarc Companies, Inc.
- Ronald and Ellen Perelman
- PGA Tour Charities, Inc.
- Lewis and Peg Ranieri
- Julian H. Robertson, Jr.
- William A. Schwartz
- M. Shanken, Chairman
- M. Shanken Communications, Inc.
- Thomas Spiegel
- Martin and Pamela Wygod

**Benefactors ($500,000 – $999,999)**
- Anonymous (3)
- Ronald W. Burkle
- Winston H. Chen, Ph.D.
- Clifton S. Robbins Charitable Fund
- Edward P. Evans Foundation
- Lawrence J. Ellison
- Sue Gin
- D. Wayne and Anne Gittinger
- Golfers Against Cancer
- Kern Family Foundation
- Rush Limbaugh
- Carol and Earle I. Mack
- Charles and Ann Mathewson
- Scott and Susan McNealy
- Gordon E. Moore
- Richard and Ellen Sandler
- Jane and Terry Semel
- Edward and Marsha Snider
- Stuart Subotnick
- Michael and Lynne Tarnopol
- Ted and Dani Virtue
- Stanley and Barbara Zax

**Patrons ($250,000 – $499,999)**
- Anonymous (1)
- Robert K. Barth
- Brian and Kathleen Bean
- Stephen and Chantal Cloobeck
- David and Sheryl Harkins Charitable Gift Fund
- L. John Doerr
- David and Marsha Ederer
- F W Mccarthy Foundation
- Howard Gittis
- Phillip and Lyn Goldstein
- Barbara J. Greenspun
- Heinz North America
- Stephen and Tomisue Hilbert
- Ray and Ghada Irani
- Joy and Jerry Monkarsh
- Family Foundation
- Peter Karmanos, Jr.
- Herb and Natalie Kohler
- C. Michael and Elizabeth Kojaian
- Lester and Sue Smith Foundation
- Richard Majasich
- Melvin and Bren Simon
- Charitable Foundation No.1
- Richard N. Merkin, M.D.
- Bruce and Jeannie Nordstrom
- Allen and Madeleine Paulson
- The R.D. and Joan Dale Hubbard Foundation
- Gene and Marianne Salmon
- Sandra and Lawrence Post Family Foundation
Mickey and Karen Shapiro
David E. and Beth Koblinner Shaw
Paul and Elle Stephens
Warren and Jale Trepp
Clyde and Vera Turner
Leslie L. Vadasz
Robert and Angela Voss
Dennis and Phyllis Washington
Gary and Karen Winnick

Partners ($100,000 – $249,999)
Anonymous (1)
William and Donna Acquavella
Phillip and Nancy Anschutz
Ambassador George L. Argyros, Sr.
Armie's Army Battles Prostate Cancer
Chris and Tony Bagdasarian
Robert and Donna Baldwin
Marc R. Benioff
Braman Family Foundation
Bristol-Myers Squibb Company
Gary S. Broad
Bruce R. and Jolene M. McCaw Fund
John and Barbara Burns
August A. Busch IV
California State Council of Laborers
Ely R. Callaway
Wayne Callaway
The Carole & Robert Daly Charitable Foundation
James and Patricia Cayne
Cendant Corporation
Max and Katharine Chapman
Concern Foundation
The David Geffen Foundation
Thomas and Gun Denhart
James and Kristin Dolan
Donaldson, Lufkin & Jenrette
Jeremy D. Eden
Eli & Edythe L. Broad Foundation
Don Engel
Ernst & Young, LLP
William F. Farley
Ferolito, Vultaggio & Sons
Ralph and Cynthia Finerman
M. Anthony and Anne Fisher
The G. Chris Andersen Family Foundation
Richard and Phyllis Gelb
Eric and Anne Gleacher
Thomas and Holly Gores
Orland S. Greene
Martin and Audrey Gruss
Richard B. Handler
Joseph W. Harch
Thomas O. Hicks
Hilton Hotels Corporation
Leo Hindery, Jr.
Jon and Karen Huntsman
Carl and Gail Icahn
Peter W. Jansen
The John F. Scarp Foundation
Joseph and Diane Steinberg 1992
Charitable Trust
Mel and Terry Karmazin
David Karpol
Michael and Jena King
Kissick Family Foundation
Knowledge Universe
Robert A. Kotick
Howard and Mary Lester
Solomon and Rosie Lew
Peter B. Lewis
The Lynn Aymar Family Foundation
Leni and Peter May
George A. Mealey
Avram Miller
S. Leslie and Barbara Misrock
Kenneth and Julie Moelis
Moore Family Foundation
Marc and Jane Nathanson
Linden Nelson
John and Sally Nordstrom
Joel M. Pashcow
Sumner and Paula Redstone
Leonard and Louise Riggio
Lew Rothman
Marc J. and Carolyn Rowan
Lewis and Rachael Rudin
Larry W. Ruvo
Haim and Cheryl Saban
salesforce.com
San Francisco Giants
Shoes for Crews
Silent Partners, Inc.
Jeffrey and Lisa Silverman
David M. Solomon
Alex G. Spanos
Avy and Marcie Stein
Ernest E. Stempel
Sterling Equities
The Stern Family Foundation
Roger and Susan Stone
Marty Tenenbaum
Laurence and Billie Tisch
Tom and Diane Tuft
Varian Associates Inc.
Viacom International, Inc.
Wade F.B. Thompson
Charitable Foundation
Leon M. Wagner
Raul and Vicki Walters
Watson, Comden, Casselman & Pearson LLP
Will and Jean Marie Weinstein
Thomas and Emily Weisel
John F. Welch, Jr.
William and Phyllis Mack
Family Foundation
Sam and Helen Zell
Selig Zises

Associates ($50,000 – $99,999)
Anonymous (4)
Robert W. Adler
Edward C. Allred
Eric J. Aronson
Michael and Marlene Aufrecht
Facundo L. Bacardi
Roger Barnett
Kathy and Frank Baxter
Erin and Douglas Becker
Samuel Belzberg
Marshall Bennett
Ken Berg
Phyllis and Martin Berman
Frank and Carol Biondi, Jr.
BlackRock Financial Management, Inc.
Dan Blumenthal
Jerry Brassfield
Shann Brassfield
Gresham T. Brebach, Jr.
CAO International, Inc.
Frank Caufield
Ray and Patti Chambers
Alfred and Kathryn Checchi
Marshall and Maureen Cogan
James H. Coleman
David and Janet Kline Fund
Michael D. Dingman
Dunwoody Senior Men’s Golf Association
Robert and Tricia Earl
Paul Fleming
Theodore J. Forstmann
Michael Frey
Jim L. Gagin
Gantcher Family Philanthropic Fund
Jeffrey Gargiulo and Valerie Boyd
Arthur and Linda Gelb
Henry and Arline Gluck
Stanley and Ilene Gold
Jeremy P. Goldberg
John and Kathleen Gorman
William and Susan Gross
Allen and Debbie Grubman
Norb Guziewicz
J. Ira and Nicki Harris
Alan and Vivien Hassenfeld
Roy W. Howard
James Hudson
The John R. & Inge P. Stafford Foundation
Joseph H. Kanter Foundation
Matthew Kaplan
John Kelley
Melvin N. Klein
Charles G. Koch
Timothy Koogler
Dewanto Kurniawan
Laborers’ International Union of North America
Lamkin Corporation
Kenneth and Linda Lay
Robert Levin
Robert E. Linton
Ira A. Lipman
Major League Baseball Charity, Inc.
Michael Marek
Martin & Toni Sosnoff Foundation
Joseph and Anne McCann
John E. McCaw
Robert A. Meister
Barry Meyer
Julie and Edward J. Minskoff
Jay and Elaine Moorin, Alain and Iris Schreiber, and ProQuest
Morongo Band of Mission Indians
Native American Rights Fund
Movado Group, Inc.
Angelo R. Mozilo
Ken Nee
Jim Newman
George and Sandra Norcross
Phil R. North
Ruth Ornstein
Jon Otto
Palermo Ravich Family Foundation
The Picower Foundation
Pritzker Foundation
Martin and Patricia Raynes
Richard S. Ressler
Tony Ressler and Jami Gertz
Mesulam Riklis
The Riordan Foundation
George R. Roberts
The Rose Foundation
Andrew M. Rosenfield
Pat and John Rosenwald
Steven and Daryl Roth
The Sam and Sarah Grossinger Foundation
David and Janelle Shaffer
Harvey L. Silbert, Esq.
Jeffrey and Helaine Silverstein
William E. and Tonia Donnelley Simon
Paul and Celia Sirotkin
Stuart M. Sloan
Eric and Susan Smidt
Don Soffer
Southern California District Council of Laborers
Saul P. Steinberg
Louis B. Susman
Swing for the Cure
Allan R. Tessler
William H. Tilley
Jeanette Trepp
Van Van Auken
Clark Van Nostrand
Alice Walton
Cheng Ching Wang
Jerry and Jane Weintraub
Jim and Kim Williams
David Yandry
Don Yannis
Zapolin Transactional Ventures, Inc.

Friends ($25,000 – $49,999)
Anonymous (1)
Don Ackerman
Norman E. Alexander
Allchin Foundation
Altadis USA, Inc.
Arby’s
Roland E. Arnall
Arthur J. Gallagher & Co.
AstraZeneca
Charles F. Baird, Jr.
Jude T. Barbera, M.D.
Robert A. Belfer
Robert and Catherine Beyer
Art H. Bilger
Tony Borhani
Denis A. Bovin
Coco Brown
Steven A. Burd
Brian P. Burns
The Cecile and Fred Bartman Foundation
Celine Dion Foundation
John Cohlan
Gregory G. Coleman
Howard Cox
Lester and Renee Crown
Edgar and Elissa Cullinan
Ian M. Cumming
Davidoff of Geneva
Robert and Kelly Day
Dendreon Corporation
Mark Donnelly
Efficiency Enterprises
Bruce Eichner
Harvey P. Eisen
Lewis M. Eisenberg
Lawrence R. Elins
The Entertainment Industry Foundation
Thomas J. Fazio
Cary Fields
Steve Fink
Bill Finneran
Alex Fisher
David N. Fleischer
Peter E. Fleming, Jr.
Todd Follmer
Theo and Constance Foltz
Fred C. Hutchinson Cancer Research Center
Jim Freer
Robert Fremont
Jerry Friedman
The Fritz and Adelaide Kauffman Foundation, Inc.
Paul R. Garcia
Philip H. Geier, Jr.
Jay Geldmacher
Stephen A. Geppi
Richard and Marcia Goldberg
Bruce Goldstein
Edward and Cheryl Gordon
Maureen V. Gorman
Greenbriar Golf Association
Wayne and Janet Gretzky
Kenneth B. Hamlet
John J. Hannan
Reed L. Harman
Ralph and Kay Hemingway
John and Susan Hess
Samuel J. Heyman
Charlie J. Horky
Hugo Boss Fashions, Inc.
Charles and Barbara Hurwitz
Vincent Iorio
IRI Golf Management, LP
Steve and Ellen Jackson
Stanley R. Jaffe
Jim Beam Brands Co.
Richard and Deborah Justice
Stephen and Marina Kaufman
Michael Klein
Henry R. Kravis
Benjamin V. Lambert
Bill Lane, Jr.
Bennett and Jerri Lebow
The Leeds Family Foundation
Steve Lehman
Joseph Rob Link
Joe Lumarda
Susan E. Lynch
Gene E. Lynn
Donald and Hilda Lytton
David S. Mack
Fredric Mack
Harvey Mackay
Bernard L. Madoff
Laurence H. Mandelbaum
Howard and Nancy Marks
Stanley and Pamela Maron
Robert and Joan Masterson
Harold Matzner
Keith W. McCaw
Michael McKeever
Richard McKenzie, Jr.
Dennis Mehiel
Merck and Co., Inc.
Herman and Susan Merinoff
Harold M. Messer, Jr.
Millennium Pharmaceuticals, Inc.
Theodore N. Miller
Michael and Cheryl Minikes
James F. Moore
Robert E. Morrow
Mark E. Mortimer
Nancy C. and Jeffrey A. Marcus Foundation, Inc.
Joseph Neubauer
Aviv Nevo
New York Mets Foundation, Inc.
John Nickoll
Chris K. Olander
Pierre and Pam Omidiyar
Peter M. Sarnoff Foundation
John and Laura Pomerantz
Mark Quigley
Richard E. Rainwater
Ramblewood Country Club
Robert and Beverly Cohen Family Foundation
Bill R. Roberts
Richard and Barbara Rosenberg
Stan and Patti Rosenthal
Eric Rothfeld
Peter H. Rothschild
Barry L. Rupp
Alvin and Marilyn Ruskin
Richard and Margaret Santulli
John H. Schnatter
Irving Schneider
Allen B. Schwartz
Stephen A. Schwarzman
Richard M. Seigel
David and F. Shapell
William Shaw
Mace and Jan Siegel
David and Lynn Silfen
Herb Simon
Fred L. Smith
Jeff P. Smith
Brian Sonnenberg
Fred and Sharon Stein
Steinberg Family Fund, Inc.
James Stern
Barry S. Sternlicht
Spencer Stokes
Burt and Mary Sugarman
Jim Tartton
Marc Utay
Wendell C. Van Auken
Peter Vegso
Michael and Laura Venable
Linda J. Wachner
Charles J. Wagner
Samuel Waksal
Vera Wang and Arthur Becker
Michael and Jill Weinstein
Stephen and Phyllis West
Gary and Nita Wexler
Rick Woolery
Don Zacharia

Supporters
($10,000 – $24,999)
Anonymous (3)
David and Kay Aaker
Paul Abecassis
S. Daniel Abraham
Abramson Family Foundation, Inc.
Gary Abramson
Joseph P. Adams, Jr.
Sheldon Adelson
Neale M. Albert, Esq.
Larry Alleto
Bruce Ambler
Lee W. Ang
Anthony & Jeanne Pritzker Family Foundation
Judd Apatow
The Armin & Esther Hirsch Foundation
Michael F. Armstrong
Victor Asad
Michael F. Ashby
Mark and Debbie Attanasio
Jerry Auerbach
Abraham Azoulay
Jeffrey C. and Lori Barakow
Sol Barer
Ron and Judy Baron
David and Judy Oliver Bash
F. Harlan Batrus
William P. Beasom, Jr.
Richard I. Beattie
Warren Beatty and Annette Benning
Gary S. Becker
Allen J. Beibee
William J. Bell
Eric L. Berg
Jeff Berg
Anthony Bergamo, Esq.
Daniel G. Bergstein
David Berkoski
Allen J. Bernstein
Les and Sheri Biller
Stanley Black
Joni Hirsch Blackman
Harvey Blau
Charles X. Block
Michael Hyatt
Royce Imhoff
International Financiers, Inc.
Herb W. Jacobs
Sheldon Jacobs
Ron Jacoby
Mr. and Mrs. Robert M. Jaffe
James S. Riepe Family Foundation
Jeffery & Nancy Lane Foundation, Inc.
Michael and Linda Jesselson
Clark A. Johnson
Allen N. Jones
Ellis B. Jones
The Judy and Howard Berkowitz Foundation
Mitch Julis
Harold Sanford Kant, Esq.
Donna Karan and Stephen Ruzow
Peter M. Kash
Howard and Susan Kaskel
David and Silvana Kay
Joshua and Joia Kazam
Dean C. Kehler
Solomon Kerzner
Gregory F. Kiernan
Brian King
Joel and Michele Kirschbaum
Daniel J. Klein
Calvin Klein
Michael and Patricia Klowden
Harold and Shirley Kobliner
A. B. Krongard
Mark Kurland
Herbert and Edythe Kurz
Gerrity Lansing
Leonard and Evelyn Lauder
William P. Lauder
Steve Lawrence and Eydie Gorme
Norman Lear
Lederman Family Foundation
Don and Rita Lee
Stephen R. Lebowitz
Len and Barbara Darling Family Fund
Alfred and Norma Lerner
Julius and Miriam Lesner
Frederick N. Levinger
Richard Levy
Loida N. Lewis
Robert Lienau
Arthur Liman
Steven Lipman
David B. Lowry
LS Management
Rufus and Patricia Lumry
Jerome D. Mack
Macy’s
John Magliocco
Peter A. Magowan
Mandalay Resort Group
Mandelbaum Foundation
Mel Mannion
Bernard Marcus
Howard and Stacy Marks
Kenneth Mazik
Larry Mazzola
Les G. McCraw, Jr.
John and Constance McGillicuddy
Thomas J. McKern
Kara McKinley
J. P. McManus
James A. McRae
Medco Containment Co.
Keith Meister
Todd Meister
Prakash Melwani
Arnon M. Ichan
Lee S. Millstein
Milton H. Dresner
Charitable Foundation
Larry A. Mizel
Robert Michael Mondavi
Charles K. Monfort
Eugene Monkash
David Moore
Jerry Moss
Mr. & Mrs. Robert Baker
Family Foundation
Wayne Mueller
Donald R. Mullen
Peter Mullin
Bill Mundel
Naples Drive for the Cure
Menasche M. Nass
Albert Neale
Rooney Nelson
New England Financial
Wayne and Kathleen Newton
NFL Charities
Perry Nisen, M.D., Ph.D.
Northern California District Council of Laborers
Marlene Nusbaum
T. D. O’Connell
Cindy K. Olson
Larry R. Palmer, CEP, CTP
Chuck Palombini
Norman J. Pattiz
Paul, Weiss, Rifkind, Wharton & Garrison, LLP
David Pecker
Gerry Pencer
Arthur Penn
Ethan Penner
Pensions 2000
Leonard C. Perham
Phoenix Home Life Mutual Insurance Company
Albert and Jeannine Pirro
Michael A. Pitino
Mack Pogue
Pohlad Family Charities
William J. Polvino, M.D.
Steve Posner
Maurice Povich and Connie Chung
Michael J. Price
Wayne Prim, Jr.
Jay Pritzker
Prometheus International, Inc.
Alan Quasha
Bruce I. Raben
Ed W. Rabin
Bruce Ratner
Michael Ratner
Randolph and Lindsey Read
John S. Reed
Denise Rich
Harold W. Ripps
Brian L. Roberts
Ralph J. Roberts
James D. Robinson III
Rodney Strong Vineyards
Gerald Ronson
Allison Rosen
Fredric and Rikki Rosen
Byron Roth
James Rothstein
Round Hill Country Club
Michel Roux
James Russell
Steve Sanak
Raymond C. Sandler
Richard Sandor
Sylvan Schefer
Andrew Scheinman
David Schneider
Raymond D. Schoenbaum
Contributors
($5,000 – $9,999)
Robert J. Abt
The Adler Family Foundation, Inc.
Advance Shared Services Center
AIM Management Group
Alvin R. Albe
Ellis J. Alde
R. Jack Alexander, Jr.
Allied Beverage Group, LLC
Arthur G. Altschul, Jr.
Ellsworth C. Alvord III
Richard and Nancy Alvord
John Angelo
Tom Armstrong
The Arthur Loeb Foundation
Phillip Asherian
Michael and Sheila Ashkin
Sherrell and Muffie Aston
Rick G. Avare
Bacardi Limited
Pam Balton
Martin Bandier
Scott P. Barasch
Alexander E. Barkas and Lynda Wijck
Janice Barney
The Barrack Foundation
Michael J. Balza, Jr.
Charles and Ruth Bauer
Ted and Ruth Baum
Lee Beattie
Bradley Bell
John and Cathi Bendheim
Walt L. and Lee Bent
Elliot Berger and Mary Schroeder
Martin S. and Karen Berger
Leonard H. Bernheim, Jr.
The Betsy and Alan Cohn Foundation, Inc.
Anthony J. Bettencourt
William C. and Sandra Bevins
Fred B. Bialek
Les and Lynn Bider
Marc Blackman
Michael and Nina Blechman
Tim and Edra Blixseth
James A. and Barbara Block
Ron Boeddeker
Franklin Otis Booth, Jr.
Kurt T. Borowsky
Richard Bougner
Larry Bowman
Thomas S. Bowman
Leonard Boxer
Stephen M. Brett
Pam Brill
Nancy Brinker
Edward Brodsky
Jeffrey and Susan Brown
Richard A. Brown
Christopher H. Browne
Richard C. Browne
Bruce E. and Robbi S. Toll Foundation
Marc R. Brutten
Deborah L. Burger, Inc.
Jack Burstein
Richard Byrd
California Community Foundation
Phil Caputo
Frank L. Cassidy, Jr.
Cell Genesys, Inc.
Clive Chajet
Michael J. Charles
Sophie Chen, Ph.D.
Bernd Chorengel
City National Bank
Clarium Capital Management, LLC
Clark & Weinstock
Greg Clark
Bert and Marilynn Cohen
Joseph M. Cohen
Richard D. Cohen
Victor A. Cohn
Michelle A. Connelly
Elaine Terner Cooper
John Cooper, Jr.
Stephen A. Cooper, DM D, Ph.D.
Peter Coors
Fred Corrado
Marshall B. Coyne
Gregory Cuneo
The Daniel Veloric Foundation
Ed DeBartolo, Jr.
Delcal Enterprises, Inc.
Jerry Della Femina
Robert Dodson
Drexel University
Daniel A. Duc
Gregory and Eileen Duch
Raymond Duncan
Joseph and Carol Ann Dvorak
Walter Eberstadt
Spencer F. Eccles
Maurits and Claire Edershaim
Anders B. Eklov
Mr. and Mrs. Alfred Engelberg
Robert and Nancy Engelberg
Yan Erikk
Aaron R. Eshman
Linda Evangelista
William F. Evans
Samer Farah, M.D.
Andrew Farkas
Jonathan Farkas
Irvng FeinTech
Robert M. Fell
James A. Ferency
Elliott Feuerstein
Gregory and Linda Fischbach
Richard B. Fisher
Stephen B. Fiverson
Karen A. Flann and Homer Schwartz
Dennis Flatt
Sam Forman
Gayle Devers Fortune
David Foster
Michael Frankel
Joel Friedland
Josh and Beth Friedman
Stephen Friedman
Robert and Ann Fromer
Richard S. Fuld, Jr.
Roy Furman
Tom W. Gamel
Howard Ganek
Lloyd and Laurel Garver
Genentech, Inc.
Georgetown Tobacco & Pipe Stores, Inc.
S. William and Barbara Gersten
Tom Giovanelli
The Honorable Rudolph W. Giuliani
Arthur M. Goldberg
Howard Goldenson
Steve A. Goldfarb
Kenneth and Barbara Goldman
Richard Goodwin
John R. Gordon
Louis and Nancy Grasmick
Jim Grau
Mark Greenhill
Howard and Dana Gurvitch
Lynn M. Haff
John Hagestad
Hall Dickler Kent Goldstein & Wood, LLP
Jesse Halperin
Fred Hameetman
Mark S. Handler
Mark S. Hanson
Martin Aaron Harmon
Gilbert and Shelley Harrison
Lauren M. Hartman
Kay Hemingway
Michael B. Hershey
Edward and Gaye Hewson
Roderick and Carla Hills
Douglas Hirsch and Holly Anderson
Peter A. Hochfelder
Richard and Jackie Hollander
Gerald Horowitz
Joe Howe
Mark Hughes
Wayne and Marti Huizenga
James and Susan Husband
George Hutchinson
Lee Iacocca
Institute for Health & Productivity
Management
Hale S. Irwin
Jeremy Jacobs
Nathan P. Jacobs
Leonard R. Jaskol
Max Javit
J. C. Earle Family Fund
Gordon W. Jenkins
Charles Jennings
JFD / MJD Golf Open
James and Lorene Jimmerson
Matthew J. Kahrhoff
Kaiser Permanente
Thomas J. Kalinske
Walter Karabian
Bruce and Sandra Karatz
Stanley and Marilyn Katz
Stephen Katz
George Kaufman
Gershon Kekst
Donald H. Keltner
Ken Roberts Company
J. Christopher Kennedy
Keys Foundation
Michael G. King, Jr.
Burton Koffman
Oswaldo Kosta
Robert Kraft
Jules B. Kroll
Norman D. Kurtz
Laborers' International Union - El Monte Local 1082
Laborers' International Union, Local 270
Laborers' International Union of North America-Local 300
Fred S. Lafer
Robert F. Lampe, Jr.
Ken Langone
Robert Larner, M.D.
Latham & Watkins
Ronald and Jo-Carole Lauder
The Laura Steinberg Tisch Foundation, Inc.
Lynn M. Leany
Frank Leanza
Ken Leese
Charles E. Leonard III
Steve Leonard
Warner LeRoy
Margaret Lesher
John A. Levin
Neil Levine
John S. Levy
David Liebowitz
Sio Lindner
Samuel S. Lionel
The Litwin Foundation, Inc.
The Loa Productions, Inc.
John L. Loeb, Jr.
Shumer Lonoff
Bob Lorsch
Lyncar Enterprises, Inc.
John Magnier
Anthony J. Magro
Brian A. Maki
Idelisse Malave
Judd Malkin
Shareef Malnik
George J. Maloof
Stuart Manheim, CPA
Stephen J. Marcus
Bernard A. Marden
Ken Martin
Kim Martindale
Elliott Masie
Norman and Joanne Matthews
Giacomo Mattoli
Caryn Mautner
Marilyn McCoo and Billy Davis, Jr.
Liam E. McGee
Robert J. McNulty
Rolf Mejer-Werner
Merrill Lynch & Company Foundation, Inc.
David A. Miller
Honorable Robert Joseph Miller
Peter H. Mills
Phillip S. Mittelman
Arthur and Patricia Modell
James J. Moglia
David Moore
Raymond Moore
Morongo Band of Mission Indians
William S. Morris III
Morton’s Restaurant Group
Harve H. Mossawir, Jr. and Judy Bardugo
Paul Motenko
Charles H. Mott
Joseph M. Murphy
Alan C. Myers
Douglas P. Nation
David Nazarian
Marty Nealon
Lee and Joyce Neibart
Mary-Rose Nelson
Nestlé Waters North America, Inc.
Blake Lee Neubauer, Ph.D.
Shilom Neuman
Chuck Nicolette, M.D.
Niebaum-Coppola Estate Winery
Douglas and Nancy Norberg
Greg Norman
Nsuh Foundation
Obermeyer Asset Management Company
James T. O’Brien
Morris Offit
John O’Hurley
Marvin Olshan
Shepard Osherow
Donald P. Pakosh
Donald and Rhoda Parmet
Partners Marketing Group
Randall Eric Paulson
David R. Pedowitz
James C. Pendergast
Mark Perlinder
Charles Persico
Robert E. Petersen
Pharmaceutical Research and Manufacturers of America
Rick Pitino
Ed Prager
Wayne Prim, Sr.
Edward Probyn
Bob Pryt
John A. Ptak
Kjell H. Qvale
Robert E. Racicot
Steve Rader
Raley’s Gold Rush Classic
Max Ramberg
Donald Rechler
Scott Greg Rechler
Joseph P. Riccardo
W. Brent and Brenda Rice
Robin Richards
Richard A. Rigg
Ritz-Carlton
Ritz-Carlton Boston
Kenn Roberts
Thomas A. Roberts
James and Linda Robinson
Sam and Mary Robson
Iber Rodriguez
Stephen M. Ross
Gordon Roth
Edward F. Rover
R. S. Evans Foundation, Inc.
Richard Ruben
Edward and Sally Rust
Denny Ryerson
Thomas L. Safran
Max Salter
Allan and Emily Sanders
Theodore and Alison Sands
Patrick Savin
Al Scheid
Schmertz Company, Inc
Alfons J. Schmitt
David M. Schoenthal
Marvin I. Schotland
David K. Schulhof
Robert Schuman
Marvin H. Schur
Gerald and Elaine Schuster
Governor Arnold Schwarzenegger and Maria Shriver
Lisa White Schweitzer
Peter W. Schweitzer
Henry Seiden
Dr. Michael E. Seiff
Martin Selig
Michael S. Shannon
Robert and Lindell Shapiro
Thomas and Medeleine Sherak
Sheri and Marc Rapaport Fund
Pam Shriver
Herbert J. Siegel
William Siegel
Adrienne W. Silver
Richard Silverman
Ronald A. Simms
David Simon
Dick Simon
James D. Sinegal
John C. Sites
Van Skilling
Joel E. Smilow
Gordon Smith
Jeff N. Smith
Arnold Snider
Steve Snyder
Southern Company Services, Inc.
Southern Wine & Spirits of Nevada, Inc.
Larry Spitcaufsky
Starbucks Coffee Company
John Stark  
Joseph Stein  
Steven E. Stern  
The Stone Family Fund  
Thomas W. Strauss  
Nancy C. Stricklin  
Chris Stuhmer  
Sunbelt Beverage Company, LLC  
Dennis A. Suskind  
Don Swirnow  
Robert R. Tanenbaum  
Stanley G. Tate  
Ian Ross Taylor  
Walter D. Tearse  
Vincent Tese  
Thomas S. Henderson and Sally S. Henderson Foundation  
Chuck B. Thornton, Jr.  
TJH  
Stanley T. Trotman, Jr.  
Cecily Truett  
Mark Truitt  
Jeffrey H. Tucker  
Turner Broadcasting System, Inc.  
Alfred Tyler II  
Peter V. Ueberroth  
William D. Unger  
Tom Unterman  
Michael J. Urfirer  
Neil G. Van Luven  
Basil K. Vasiliou  
Velos Medical Informatics, Inc.  
Mary E. Venable  
Robert A. Waller  
David E. Walters  
John Walton  
William R. Ward  
Jack L. Warner  
Roger Weber  
Raymond J. Weis  
Robert Weiss  
Jay Weitzman  
Miles D. White  
Gary L. Wilson  
Daniel P. Wimsatt  
Andrew Wise  
Moira Wolofsky  
Douglas J. Wood  
Rodney A. Wray  
Bud and Cynthia Yorkin  
Stan Zicklin

Pharmaceutical, Biotechnology and Device Sponsors

PCF Pharmaceutical Industry Roundtable  
Abbott Laboratories  
Aventis  
Novartis Oncology  
Sanofi-Synthelabo

11th Annual Scientific Retreat  
Gold Sponsors  
Abbott Laboratories  
Aventis  
Bristol-Myers Squibb Company  
Novartis Oncology  
OSI Pharmaceuticals  
Silver Sponsors  
Millennium  
Sanofi-Synthelabo

Other  
Cytogen Corporation  
Dendreon  
Oncura  
Ortho Biotech, Inc.  
Tibotech Therapeutics  
TomoTherapy, Inc.  
Varian Medical Systems, Inc.
PRESIDENTIAL BOARD

Mike Milken
Founder and Chairman
Prostate Cancer Foundation

James Blair
General Partner
Domain Associates

S. Ward (Trip) Casscells III, M.D.
John Edward Tyson Distinguished Professor of Medicine and Vice President of Biotechnology
University of Texas HSC, Houston

David Ederer
Chairman
Ederer Investment Company

Sue Gin
Chairman and Chief Executive Officer
Flying Food Group, Inc.

The Reverend Rosey Grier
The Milken Family Foundation

Andrew Grove
Chairman
Intel Corporation

Stuart Holden, M.D.
Director
Cedars-Sinai
Louis Warschaw Prostate Cancer Center
Warschaw, Robertson, Law Families Chair in Prostate Cancer
Cedars-Sinai Medical Center

Arthur Kern
Investor

David Koch
Executive Vice President
Koch Industries

Jeffrey A. Marcus
Partner
Crestview Capital Partners

Shmuel Meitar
Director
Aurec Group

BOARD OF DIRECTORS

Gerald Ford

Jimmy Carter

George H. W. Bush

Bill Clinton
**EXECUTIVE MANAGEMENT**

*Leslie D. Michelson*
Vice Chairman and
Chief Executive Officer

*Ralph Finerman*
Secretary, Treasurer and
Chief Financial Officer

*Debbie J. Bohnett*
Chief Operating Officer

*Craig Dionne, Ph.D.*
Executive Vice President
of Research and Therapeutics

*Stuart Holden, M.D.*
Medical Director

*Gregg S. Britt*
Senior Vice President,
Biopharmaceutical
Research and Development

*Karen Stone*
Senior Vice President,
Development

*Scott Harvey*
Senior Vice President,
Corporate Alliances

*Sarah Z. Evans*
Vice President,
Communications

*Jan Haber*
Vice President, Events
and Donor Relations

*Helen Hsieh*
Vice President, Finance
and Administration

*Martin Erck*
Vice President, Special Projects

---

**Leslie D. Michelson**
Vice Chairman and
Chief Executive Officer

**Ralph Finerman**
Secretary, Treasurer and
Chief Financial Officer

**Debbie J. Bohnett**
Chief Operating Officer

**Craig Dionne, Ph.D.**
Executive Vice President
of Research and Therapeutics

**Stuart Holden, M.D.**
Medical Director

**Gregg S. Britt**
Senior Vice President,
Biopharmaceutical
Research and Development

**Karen Stone**
Senior Vice President,
Development

**Scott Harvey**
Senior Vice President,
Corporate Alliances

**Sarah Z. Evans**
Vice President,
Communications

**Jan Haber**
Vice President, Events
and Donor Relations

**Helen Hsieh**
Vice President, Finance
and Administration

**Martin Erck**
Vice President, Special Projects
APPEAL FOR SUPPORT

The PCF is making measurable strides to beat cancer, but to reach the ultimate goal—a cure for recurrent prostate cancer—we need your help.

To defeat prostate cancer once and for all, the PCF is committed to harnessing as many human and financial resources as possible. This includes corporations, major donors and, yes, you. Everyone can, and does, make a difference.

It takes all kinds of people to support the PCF. People whose loved ones—husbands, fathers, brothers, sons—have prostate cancer. People worried that one day they, or other men in their lives, will be diagnosed with this all-too-common disease. Industry leaders. Famous athletes. The man on the street.

With your help, we will figure out why so many men get prostate cancer, and why it is far more life-threatening to some men than to others.

With your help, we will bring down the current barriers to completing clinical trials for new prostate cancer drugs and win regulatory approval for them.

With your help, we will make sure that every man with prostate cancer has access to the latest treatments and that doctors treating the disease are up-to-date on the most current advances in care.

With your help, we will provide vital early funding for experimental prostate cancer treatments for intractable cases of advanced prostate cancer.

There's no time to waste, so please act now.

The PCF welcomes memorial or tribute gifts in honor of friends or loved ones, as well as monetary donations, donations of non-cash assets and bequests.
2004 WAS A REMARKABLE YEAR.

- Fortune featured the PCF in its November cover story entitled “Beating Cancer,” and named the PCF as its official philanthropy to celebrate its 75th anniversary.
- For the first time ever, the U.S. Food and Drug Administration approved a drug (Taxotere) that extends life for men with advanced prostate cancer.
- The PCF expanded its donor base by 35%.
- And, significant progress was made in demonstrating the link between nutrition, especially antioxidants, and prostate cancer.

Donations

Please mail your check to:
Prostate Cancer Foundation
1250 Fourth Street
Santa Monica, California 90401

To make an online contribution, please visit our Web site: prostatecancerfoundation.org.

To make a credit card donation, call 800.757.CURE.

Memorial or Tribute Gifts

Honor the memory of a loved one or celebrate the accomplishment of a friend or family member by helping others.

Make a memorial or tribute gift and the PCF will send an acknowledgment card to the family of the honoree.

Other Gift Suggestions

- Assets or property including appreciated stock and real estate.
- Bequest—Include a gift to the PCF in your will.
- Name the PCF as the primary or contingent beneficiary on a life insurance policy.

Editors: Sarah Evans, Jessica Niebauer
Contributor: Jon Greer
Special Thanks: Aaron Ciechanover, M.D., D.Sc., Steven Bark, Dave Callery, Ph.D., Jenny Graw, Beth Kobliner Shaw, Nelson Peltz, Marvin R. Shanken, Wade F. Thompson, Joe Torre
Photography: Michael D’Ambrosio
Design: KBDI, Los Angeles
More information: prostatecancerfoundation.org